BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34839520)

  • 41. NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia.
    Yi ES; Choi YB; Choi R; Lee NH; Lee JW; Yoo KH; Sung KW; Lee SY; Koo HH
    Cancer Res Treat; 2018 Jul; 50(3):872-882. PubMed ID: 28903549
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
    Tantawy AA; El-Bostany EA; Adly AA; Abou El Asrar M; El-Ghouroury EA; Abdulghaffar EE
    Blood Coagul Fibrinolysis; 2010 Jan; 21(1):28-34. PubMed ID: 19923983
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of polymorphisms in transporter genes on dosing, efficacy and toxicity of maintenance therapy in children with acute lymphoblastic leukemia.
    Gervasini G; de Murillo SG; Jiménez M; de la Maya MD; Vagace JM
    Gene; 2017 Sep; 628():72-77. PubMed ID: 28710036
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association Between Combined Presence of Hepatitis C Virus and Polymorphisms in Different Genes With Toxicities of Methotrexate and 6-Mercaptopurine in Children With Acute Lymphoblastic Leukemia.
    Abdelaziz DH; Elhosseiny NM; Khaleel SA; Sabry NA; Attia AS; El-Sayed MH
    Pediatr Blood Cancer; 2016 Sep; 63(9):1539-45. PubMed ID: 27163515
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thiopurine S-methyltransferase (TPMT) polymorphisms in children with acute lymphoblastic leukemia, and the need for reduction or cessation of 6-mercaptopurine doses during maintenance therapy: the Polish multicenter analysis.
    Peregud-Pogorzelski J; Tetera-Rudnicka E; Kurzawski M; Brodkiewicz A; Adrianowska N; Mlynarski W; Januszkiewicz D; Drozdzik M
    Pediatr Blood Cancer; 2011 Oct; 57(4):578-82. PubMed ID: 21319286
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia.
    Zhou Y; Wang L; Zhai XY; Wen L; Tang F; Yang F; Liu XT; Dong L; Zhi LJ; Shi HY; Hao GX; Zheng Y; Jacqz-Aigrain E; Wang TY; Zhao W
    Br J Clin Pharmacol; 2020 Aug; 86(8):1519-1527. PubMed ID: 32077136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low NUDT15 expression levels due to biallelic NUDT15 variants and 6-mercaptopurine intolerance.
    Yoshida M; Brown SA; Moriyama T; Nishii R; Tsujimoto SI; Yamada Y; Yoshida K; Shirai R; Osumi T; Utano T; Fukano R; Kudo K; Sakaguchi K; Arakawa Y; Koh K; Sekiguchi M; Sekimizu M; Miyamura T; Ishida H; Inukai T; Tomizawa D; Kiyokawa N; Kato M; Yang JJ
    Br J Haematol; 2022 Oct; 199(2):270-276. PubMed ID: 35905175
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NUDT15 c.415C>T increases risk of 6-mercaptopurine induced myelosuppression during maintenance therapy in children with acute lymphoblastic leukemia.
    Chiengthong K; Ittiwut C; Muensri S; Sophonphan J; Sosothikul D; Seksan P; Suppipat K; Suphapeetiporn K; Shotelersuk V
    Haematologica; 2016 Jan; 101(1):e24-6. PubMed ID: 26405151
    [No Abstract]   [Full Text] [Related]  

  • 49. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity.
    Moriyama T; Nishii R; Perez-Andreu V; Yang W; Klussmann FA; Zhao X; Lin TN; Hoshitsuki K; Nersting J; Kihira K; Hofmann U; Komada Y; Kato M; McCorkle R; Li L; Koh K; Najera CR; Kham SK; Isobe T; Chen Z; Chiew EK; Bhojwani D; Jeffries C; Lu Y; Schwab M; Inaba H; Pui CH; Relling MV; Manabe A; Hori H; Schmiegelow K; Yeoh AE; Evans WE; Yang JJ
    Nat Genet; 2016 Apr; 48(4):367-73. PubMed ID: 26878724
    [TBL] [Abstract][Full Text] [Related]  

  • 50. NUDT15 polymorphism in healthy children with Bai nationality in Yunnan of China.
    Pu G; Wang Y; Duan S; Chen J; Yang C; Cui T; Fang C; Zhou Y; Zhang H; Tian X
    Pediatr Int; 2021 Jul; 63(7):790-796. PubMed ID: 32969567
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of FTO polymorphism in 6-mercaptopurine related intolerance in children with acute lymphoblastic leukemia.
    Singh M; Bhaskar D; Bhatia P; Thakur R; Sharma P; Bansal D; Jain R; Trehan A
    Cancer Chemother Pharmacol; 2023 Jul; 92(1):51-56. PubMed ID: 37256334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Susceptibility to thiopurine toxicity by
    Correa-Jimenez O; Yunis JJ; Linares-Ballesteros A; Sarmiento-Urbina I
    Colomb Med (Cali); 2021; 52(3):e2074569. PubMed ID: 35431360
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Individualized Use of 6-Mercaptopurine in Chinese Children with ALL: A Multicenter Randomized Controlled Trial.
    Zhou Y; Wang L; Sun LR; Zhang L; Wang HM; Liu XT; Yang F; Wu KL; Liang YL; Zhao BB; Zhuang Y; Fu JQ; Song C; Li Y; Wang LZ; Xu HJ; Gu Y; van den Anker J; Ju XL; Zhu XF; Zhao W
    Clin Pharmacol Ther; 2024 Feb; 115(2):213-220. PubMed ID: 37753808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children.
    Tanaka Y; Manabe A; Nakadate H; Kondoh K; Nakamura K; Koh K; Utano T; Kikuchi A; Komiyama T
    Leuk Res; 2012 May; 36(5):560-4. PubMed ID: 22200619
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical evaluation of
    Nishii R; Moriyama T; Janke LJ; Yang W; Suiter CC; Lin TN; Li L; Kihira K; Toyoda H; Hofmann U; Schwab M; Takagi M; Morio T; Manabe A; Kham S; Jiang N; Rabin KR; Kato M; Koh K; Yeoh AE; Hori H; Yang JJ
    Blood; 2018 May; 131(22):2466-2474. PubMed ID: 29572377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine.
    Khaeso K; Komvilaisak P; Chainansamit SO; Nakkam N; Suwannaying K; Kuwatjanakul P; Hikino K; Dornsena A; Kanjanawart S; Laoaroon N; Vannaprasaht S; Taketani T; Tassaneeyakul W
    Drug Metab Pharmacokinet; 2022 Apr; 43():100436. PubMed ID: 35016134
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA-thioguanine nucleotide as a treatment marker in acute lymphoblastic leukemia patients with NUDT15 variant genotypes.
    Ju HY; Lee JW; Cho HW; Hyun JK; Ma Y; Yi ES; Yoo KH; Sung KW; Choi R; Koo HH; Lee SY
    PLoS One; 2021; 16(1):e0245667. PubMed ID: 33481917
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of NUDT15 gene variants in Amazonian Amerindians and admixed individuals from northern Brazil.
    Rodrigues JCG; Souza TP; Pastana LF; Ribeiro Dos Santos AM; Fernandes MR; Pinto P; Wanderley AV; Souza SJ; Kroll JE; Pereira AL; Magalhães L; Mercês LRD; Vidal AF; Vinasco-Sandoval T; Cavalcante GC; Guerreiro JF; Assumpção PP; Ribeiro-Dos-Santos Â; Santos S; Santos NPCD
    PLoS One; 2020; 15(4):e0231651. PubMed ID: 32294118
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hispanic ethnicity and the rs4880 variant in SOD2 are associated with elevated liver enzymes and bilirubin levels in children receiving asparaginase-containing chemotherapy for acute lymphoblastic leukemia.
    Wu S; Wang M; Alqahtani A; Lou M; Stock W; Bhojwani D; Alachkar H
    Biomed Pharmacother; 2022 Jun; 150():113000. PubMed ID: 35658244
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NUDT15 polymorphism and NT5C2 and PRPS1 mutations influence thiopurine sensitivity in acute lymphoblastic leukaemia cells.
    Somazu S; Tanaka Y; Tamai M; Watanabe A; Kagami K; Abe M; Harama D; Shinohara T; Akahane K; Goi K; Sugita K; Moriyama T; Yang J; Goto H; Minegishi M; Iwamoto S; Takita J; Inukai T
    J Cell Mol Med; 2021 Nov; 25(22):10521-10533. PubMed ID: 34636169
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.